Discovery of potent, orally bioavailable, selective 5-HT1A/B/D receptor antagonists

被引：10

作者：

Ward, Simon E. ^{[1
]}

Eddershaw, Peter J. ^{[1
]}

Scott, Claire M. ^{[1
]}

Gordon, Laurie J. ^{[1
]}

Lovell, Peter J. ^{[1
]}

Moore, Susan H. ^{[1
]}

Smith, Paul W. ^{[1
]}

Starr, Kathryn R. ^{[1
]}

Thewlis, Kevin M. ^{[1
]}

Watson, Jeannette M. ^{[1
]}

机构：

[1] GlaxoSmithKline, Psychiat Ctr Excellence Drug Discovery & Mol Disc, Harlow CM19 5AW, Essex, England

来源：

JOURNAL OF MEDICINAL CHEMISTRY | 2008年 / 51卷 / 10期

关键词：

D O I：

10.1021/jm8001444

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

5-HT1 receptor antagonists have been discovered with good selectivity over the 5-HT transporter. This is the first report of highly potent, selective ligands for the 5-HT1A/B/D receptors with low intrinsic activity, which represent a useful set of molecules for further understanding the roles of the 5-HT1 receptor subtypes and providing new approaches,for the treatment of depression.

引用

页码：2887 / 2890

页数：4

共 50 条

[31] 5-HT1A receptor antagonists and lordosis behavior
Uphouse, L
Andrade, M
CaldarolaPastuszka, M
Jackson, A
[J]. NEUROPHARMACOLOGY, 1996, 35 (04) : 489 - 495
[32] Indoloxypropanolamine analogues as 5-HT1A receptor antagonists
Krushinski, Joseph H., Jr.
Schaus, John M.
Thompson, Dennis C.
Calligaro, David O.
Nelson, David L.
Luecke, Susan H.
Wainscott, David B.
Wong, David T.
[J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2007, 17 (20) : 5600 - 5604
[33] Discovery of orally active, potent, and selective CB1 antagonists
Jayne, Charles L.
Xia, Yan
Vaccaro, Henry A.
Chackalamannil, Samuel
Greenlee, William
Boykow, George
Duffy, Ruth
Kowalski, Timothy
Spar, Brian
Cui, Xiaoming
[J]. ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2012, 244
[34] Discovery of a new class of potent, selective, and orally active prostaglandin D2 receptor antagonists
Torisu, K
Kobayashi, K
Iwahashi, M
Nakai, Y
Onoda, T
Nagase, T
Sugimoto, I
Okada, Y
Matsumoto, R
Nanbu, F
Ohuchida, S
Nakai, H
Toda, M
[J]. BIOORGANIC & MEDICINAL CHEMISTRY, 2004, 12 (20) : 5361 - 5378
[35] 5-HT1B/D receptor antagonists
Pauwels, PJ
[J]. GENERAL PHARMACOLOGY-THE VASCULAR SYSTEM, 1997, 29 (03): : 293 - 303
[36] Discovery of potent and orally bioavailable N,N′-diarylurea antagonists for the CXCR2 chemokine receptor
Jin, Q
Nie, H
McCleland, BW
Widdowson, KL
Palovich, MR
Elliott, JD
Goodman, RM
Burman, M
Sarau, HM
Ward, KW
Nord, M
Orr, BM
Gorycki, PD
Busch-Petersen, J
[J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2004, 14 (17) : 4375 - 4378
[37] Discovery and Characterization of RGH-122, a Potent, Selective, and Orally Bioavailable V1a Receptor Antagonist
Baska, Ferenc
Bozo, Eva
Szeleczky, Zsolt
Szanto, Gabor
Vukics, Krisztina
Szakacs, Zoltan
Domany-Kovacs, Katalin
Kurko, Dalma
Vass, Elemer
Than, Marta
Vastag, Monika
Temesvari, Krisztina
Levai, Sandor
Halasz, Attila Sandor
Kordas, Krisztina Szondine
Roman, Viktor
Greiner, Istvan
Bata, Imre
[J]. JOURNAL OF MEDICINAL CHEMISTRY, 2024, 67 (01) : 643 - 673
[38] SB-272183, a selective 5-HT1A, 5-HT1B and 5-HT1D receptor antagonist.
Roberts, C
Watson, J
Scott, C
Collin, L
Harries, MH
Wyman, P
Gaster, L
Price, GW
Midlemiss, DN
[J]. BRITISH JOURNAL OF PHARMACOLOGY, 2001, 133 : U76 - U76
[39] Synthesis and biological evaluation of benzodioxanylpiperazine derivatives as potent serotonin 5-HT1A antagonists:: The discovery of lecozotan
Childers, WE
Abou-Gharbia, MA
Kelly, MG
Andree, TH
Harrison, BL
Ho, DM
Hornby, G
Huryn, DM
Potestio, L
Rosenzweig-Lipson, SJ
Schmid, J
Smith, DL
Sukoff, SJ
Zhang, G
Schechter, LE
[J]. JOURNAL OF MEDICINAL CHEMISTRY, 2005, 48 (10) : 3467 - 3470
[40] Studies on a series of potent, orally bioavailable, 5-HT1 receptor ligands-Part II
Ward, Simon E.
Eddershaw, Peter
Flynn, Sean T.
Gordon, Laurie
Lovell, Peter J.
Moore, Susan H.
Scott, Claire M.
Smith, Paul W.
Thewlis, Kevin M.
Wyman, Paul A.
[J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2009, 19 (02) : 428 - 432

← 1 2 3 4 5 →